| Primary |
| Breast Cancer |
81.5% |
| Breast Cancer Metastatic |
12.5% |
| Ovarian Cancer |
1.1% |
| Ovarian Cancer Recurrent |
1.1% |
| Cardiac Disorder |
0.5% |
| Depression |
0.5% |
| Gout |
0.5% |
| Hyperlipidaemia |
0.5% |
| Hypertension |
0.5% |
| Lower Urinary Tract Symptoms |
0.5% |
| Platelet Aggregation |
0.5% |
|
| Palmar-plantar Erythrodysaesthesia Syndrome |
10.0% |
| Pneumonia |
10.0% |
| White Blood Cell Count Decreased |
10.0% |
| Organising Pneumonia |
6.7% |
| Pancytopenia |
6.7% |
| Pyrexia |
6.7% |
| Stomatitis |
6.7% |
| Abscess Jaw |
3.3% |
| Alveolitis |
3.3% |
| Aplasia |
3.3% |
| Cellulitis |
3.3% |
| Cerebral Haemorrhage |
3.3% |
| Chills |
3.3% |
| Cholangitis Suppurative |
3.3% |
| Colitis |
3.3% |
| Encephalitis |
3.3% |
| Extravasation |
3.3% |
| Fatigue |
3.3% |
| Gastroenteritis |
3.3% |
| Hepatic Enzyme Increased |
3.3% |
|
| Secondary |
| Breast Cancer |
47.7% |
| B-cell Lymphoma |
22.3% |
| Breast Cancer Metastatic |
5.6% |
| Diffuse Large B-cell Lymphoma |
5.6% |
| Product Used For Unknown Indication |
3.7% |
| Breast Neoplasm |
3.5% |
| Hypertension |
2.6% |
| Non-hodgkin's Lymphoma |
1.4% |
| Chemotherapy |
1.0% |
| Drug Use For Unknown Indication |
1.0% |
| Prophylaxis |
1.0% |
| Her-2 Positive Breast Cancer |
0.7% |
| Palliative Care |
0.7% |
| Nausea |
0.6% |
| Asthma |
0.5% |
| Breast Cancer Stage Iv |
0.5% |
| Disease Progression |
0.5% |
| Antiemetic Supportive Care |
0.3% |
| Fluid Replacement |
0.3% |
| Hormone Therapy |
0.3% |
|
| Pyrexia |
16.8% |
| Neutropenia |
14.1% |
| Febrile Neutropenia |
11.4% |
| Leukopenia |
6.0% |
| General Physical Health Deterioration |
5.4% |
| Thrombocytopenia |
5.4% |
| Stomatitis |
4.7% |
| Deep Vein Thrombosis |
4.0% |
| Lung Adenocarcinoma |
4.0% |
| Lung Adenocarcinoma Stage I |
4.0% |
| Sepsis |
4.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
3.4% |
| Hepatic Enzyme Increased |
2.7% |
| Leukocytosis |
2.7% |
| Mucosal Inflammation |
2.7% |
| Pneumonia |
2.0% |
| Somnolence |
2.0% |
| Tachycardia |
2.0% |
| Anaemia |
1.3% |
| Diarrhoea |
1.3% |
|
| Concomitant |
| Breast Cancer |
35.7% |
| Breast Cancer Metastatic |
14.3% |
| Drug Use For Unknown Indication |
7.1% |
| Non-hodgkin's Lymphoma |
7.1% |
| Leiomyosarcoma Metastatic |
5.7% |
| Synovial Sarcoma Metastatic |
5.7% |
| Ovarian Cancer |
4.3% |
| Neutropenia |
2.9% |
| Prophylaxis |
2.9% |
| Acquired Immunodeficiency Syndrome |
1.4% |
| Allergy Prophylaxis |
1.4% |
| Bone Disorder |
1.4% |
| Breast Cancer Recurrent |
1.4% |
| Diffuse Large B-cell Lymphoma |
1.4% |
| Hodgkin's Disease |
1.4% |
| Nausea |
1.4% |
| Product Used For Unknown Indication |
1.4% |
| T-cell Lymphoma |
1.4% |
| Vomiting |
1.4% |
|
| Neurotoxicity |
9.1% |
| Splenic Infarction |
9.1% |
| Disease Progression |
4.5% |
| Drug Ineffective |
4.5% |
| Erythema |
4.5% |
| Febrile Neutropenia |
4.5% |
| Metastases To Lung |
4.5% |
| Neoplasm Progression |
4.5% |
| Neutrophil Count Decreased |
4.5% |
| Pain In Jaw |
4.5% |
| Primary Sequestrum |
4.5% |
| Purulent Discharge |
4.5% |
| Pyrexia |
4.5% |
| Quadriparesis |
4.5% |
| Stevens-johnson Syndrome |
4.5% |
| Syncope |
4.5% |
| Tachycardia |
4.5% |
| Tooth Extraction |
4.5% |
| Transaminases Increased |
4.5% |
| Urticaria |
4.5% |
|
| Interacting |
|
| Palmar-plantar Erythrodysaesthesia Syndrome |
100.0% |
|
